title: Pill Burden in Patients With Type 2 Diabetes in Germany: Subanalysis From the Prospective, Noninterventional PROVIL Study.
abstract: IN BRIEF Type 2 diabetes and its associated comorbidities often require polypharmacotherapy, which may result in poor adherence to treatment. This study evaluated, using subjective patient and physician questionnaire surveys, the impact of pill burden and its associated consequences on patients treated with vildagliptin as add-on to metformin, a fixed-dose combination of vildagliptin/metformin, or another dual oral antidiabetic therapy. Patients' responses were also analyzed by age (<65 or ≥65 years). The surveys revealed that a high pill count in antidiabetic therapy constitutes a large burden for patients with type 2 diabetes. Treating physicians are aware of the problems that result from a high pill burden, and a majority of them prefer prescribing fixed-dose combinations that have better efficacy and tolerability to reduce pill burden.
authors.affiliation: Universitätsklinikum [University Medical Center], Leipzig, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Blüher
authors.affiliation: Kantar Health GmbH, Munich, Germany.
authors.forename: Ira
authors.initials: I
authors.lastname: Kurz
authors.affiliation: Clinical and Regulatory Affairs, Novartis Pharma GmbH, Nürnberg, Germany.
authors.forename: Simone
authors.initials: S
authors.lastname: Dannenmaier
authors.affiliation: Clinical and Regulatory Affairs, Novartis Pharma GmbH, Nürnberg, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Dworak